CD30在淋巴瘤中的表达及检测：现状与挑战

doi:10.19401/j.cnki.1007-3639.2022.06.005

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (6): 512-518.doi: 10.19401/j.cnki.1007-3639.2022.06.005

CD30在淋巴瘤中的表达及检测：现状与挑战

李小秋()(), CD30阳性淋巴瘤病理专家组

复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032

收稿日期:2022-03-07 修回日期:2022-05-30 出版日期:2022-06-30 发布日期:2022-07-21
通信作者: 李小秋,CD30阳性淋巴瘤病理专家组 E-mail:leexiaoqiu@hotmail.com
作者简介:李小秋,医学博士,主任医师、教授、博士研究生导师。现任复旦大学附属肿瘤医院病理科副主任、淋巴造血病理专科负责人。现兼任中国国家卫生健康委能力建设和继续教育中心淋巴瘤专科建设项目专家组顾问暨病理学组组长、中国抗癌协会淋巴瘤专业委员会副主任委员、中国抗癌协会血液肿瘤专业委员会常务委员暨滤泡性淋巴瘤工作组副主任委员、中国临床肿瘤学会淋巴瘤专家委员会常务委员、中华医学会病理学分会淋巴造血系统病理学组顾问、中华医学会肿瘤学分会淋巴血液学组委员、中国老年保健协会淋巴瘤专业委员会常务委员、中国医疗保健国际交流促进会病理专业委员会常务委员、上海市抗癌协会淋巴瘤专业委员会副主任委员、上海医药行业协会血液医学转化专业委员会常务委员。参与执笔《WHO造血淋巴肿瘤分类》（2022年）、《WHO头颈部肿瘤分类》（2017年、2022年）、《WHO消化系统肿瘤分类》（2019年）及《WHO皮肤肿瘤分类》（2023年）章节。

Detection of CD30 expression in lymphomas: status and challenges

LI Xiaoqiu()(), CD30 Positive Lymphoma Pathology Expert Group

Department of Pathology, Fudan University Shanghai Cancer Center; Department ofOncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2022-03-07 Revised:2022-05-30 Published:2022-06-30 Online:2022-07-21
Contact: LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group E-mail:leexiaoqiu@hotmail.com

摘要/Abstract

摘要：

CD30是肿瘤坏死因子受体超家族成员,在经典型霍奇金淋巴瘤（classical Hodgkin lymphoma,CHL）、间变性大细胞淋巴瘤（anaplastic large cell lymphoma,ALCL）等多种淋巴瘤中均有不同程度的表达。除了作为诊断和评价预后的标志物,CD30还是抗体药物偶联物的有效靶点。随着以CD30为治疗靶点的多项临床试验相继开展,淋巴瘤CD30表达水平的规范化检测日益重要。本文综述了CD30在不同类型淋巴瘤中的表达特征以及CD30在检测和判读方面所面临的挑战及可能的解决方案。

关键词: 淋巴瘤, CD30, 生物标志物, 靶向治疗

Abstract:

CD30, a member of tumor necrosis factor receptor family, is expressed in a variety of lymphoma subtypes, such as classic Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL). In addition to its diagnostic and prognostic values, CD30 has now been recognized as an effective target for antibody drug conjugate (ADC). With the progress of multiple clinical trials involving the anti-CD30-targeted therapy, a standardized detection and assessment of CD30 expression in lymphoma cases appear necessary. We thus reviewed in this article the CD30 expression patterns and the challenges on the CD30 detection and assessment in different lymphomas.

Key words: Lymphoma, CD30, Biomarker, Targeted therapy

中图分类号:

R733.4

李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测：现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.

LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges[J]. China Oncology, 2022, 32(6): 512-518.

图/表 2

表1

表2

参考文献 36

[1]	HORIE R,, AIZAWA S,, NAGAI M, et al. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation[J]. Int Immunol, 1998, 10(2): 203-210. doi: 10.1093/intimm/10.2.203
[2]	VAN DER WEYDEN C A, PILERI S A,, FELDMAN A L, et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions[J]. Blood Cancer J, 2017, 7(9): e603. doi: 10.1038/bcj.2017.85
[3]	ROMAGNANI P,, ANNUNZIATO F,, MANETTI R, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus[J]. Blood, 1998, 91(9): 3323-3332. doi: 10.1182/blood.V91.9.3323
[4]	BOWEN M A,, LEE R K,, MIRAGLIOTTA G, et al. Structure and expression of murine CD30 and its role in cytokine production[J]. J Immunol, 1996, 156(2): 442-449.
[5]	PIERCE J M,, MEHTA A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma[J]. Expert Rev Hematol, 2017, 10(1): 29-37. doi: 10.1080/17474086.2017.1270202
[6]	FEDERICO M,, BELLEI M,, LUMINARI S, et al. CD30⁺ expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-Cell Project[J]. J Clin Oncol, 2015, 33(15_suppl): 8552. doi: 10.1200/jco.2015.33.15_suppl.8552
[7]	PONGPRUTTIPAN T,, KUMMALUE T,, BEDAVANIJA A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand[J]. Diagn Pathol, 2011, 6: 79. doi: 10.1186/1746-1596-6-79
[8]	FERRERI A J M,, GOVI S,, PILERI S A, et al. Anaplastic large cell lymphoma, ALK-positive[J]. Crit Rev Oncol, 2012, 83(2): 293-302. doi: 10.1016/j.critrevonc.2012.02.005
[9]	DELSOL G,, FALINI B,, MULLERHERMELINK HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO classification of tumours of haematopoietic & lymphoid tissues, 2008[EB/OL].[2008-01-01].https://www.researchgate.net/scientific-contributions/HK-Muller-Hermelink-2127932347 .
[10]	SABATTINI E,, PIZZI M,, TABANELLI V, et al. CD30 expression in peripheral T-cell lymphomas[J]. Haematologica, 2013, 98(8): e81-e82.
[11]	EDINGER J T,, CLARK B Z,, PUCEVICH B E, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides[J]. Am J Surg Pathol, 2009, 33(12): 1860-1868. doi: 10.1097/PAS.0b013e3181bf677d
[12]	CERRONI L,, RIEGER E,, HÖDL S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma[J]. Am J Surg Pathol, 1992, 16(6): 543-552. doi: 10.1097/00000478-199206000-00002
[13]	EL SHABRAWI-CAELEN L, KERL H,, CERRONI L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C[J]. Arch Dermatol, 2004, 140(4): 441-447.
[14]	SLACK G W,, STEIDL C,, SEHN L H, et al. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia[J]. Br J Haematol, 2014, 167(5): 608-617. doi: 10.1111/bjh.13085
[15]	CAMPUZANO-ZULUAGA G,, CIOFFI-LAVINA M,, LOSSOS I S, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases[J]. Leuk Lymphoma, 2013, 54(11): 2405-2411. doi: 10.3109/10428194.2013.778407
[16]	HU S M,, XU-MONETTE Z Y,, BALASUBRAMANYAM A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL rituximab-CHOP consortium program study[J]. Blood, 2013, 121(14): 2715-2724. doi: 10.1182/blood-2012-10-461848
[17]	HIGGINS J P,, WARNKE R A. CD30 expression is common in mediastinal large B-cell lymphoma[J]. American J Clin Pathol, 1999, 112(2): 241-247. doi: 10.1093/ajcp/112.2.241
[18]	GARDNER L J,, POLSKI J M,, EVANS H L, et al. CD30 expression in follicular lymphoma[J]. Archiv Pathol Laboratory Med, 2001, 125(8): 1036-1041. doi: 10.5858/2001-125-1036-CEIFL
[19]	ANSELL S M. Hodgkin lymphoma: diagnosis and treatment[J]. Mayo Clin Proc, 2015, 90(11): 1574-1583. doi: 10.1016/j.mayocp.2015.07.005
[20]	MORA J,, FILIPPA D A,, THALER H T, et al. Large cell non-Hodgkin lymphoma of childhood[J]. Cancer, 2000, 88(1): 186-197. doi: 10.1002/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5
[21]	KRAUSE J R. WHO classification of tumours of haematopoietic and lymphoid tissues: an overview[J]. Crit Values, 2015, 2(2): 30-32.
[22]	WEISENBURGER D D,, SAVAGE K J,, HARRIS N L, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project[J]. Blood, 2011, 117(12): 3402-3408. doi: 10.1182/blood-2010-09-310342
[23]	HOFFBRAND A,, CATOVSKY D,, TUDDENHAM E, et al. Appendix Ⅱ: World Health Organization classification of tumours of the haematopoietic and lymphoid tissues[EB/OL]. https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b , 2010.
[24]	FALINI B,, PILERI S,, PIZZOLO G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy[J]. Blood, 1995, 85(1): 1-14. doi: 10.1182/blood.V85.1.1.bloodjournal8511
[25]	EL-SAYED A M,, EL-BORAI M H,, BAHNASSY A A, et al. Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry[J]. Diagn Pathol, 2008, 3: 43. doi: 10.1186/1746-1596-3-43 pmid: 18986555
[26]	Nordic Immunohistochemical Quality Control, CD30 run 51 2017.[EB/OL].[2017-11-27]. https://www.nordiqc.org/downloads/assessments/90_5.pdf
[27]	LI B,, ESCHRICH S A,, BERGLUND A, et al. Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility[J]. JMIR Res Protoc, 2017, 6(3): e45.
[28]	XU M L,, GABALI A,, HSI E D, et al. Practical approaches on CD30 detection and reporting in lymphoma diagnosis[J]. Am J Surg Pathol, 2020, 44(2): e1-e14.
[29]	HORWITZ S,, O'CONNOR O A,, PRO B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168): 229-240. doi: 10.1016/S0140-6736(18)32984-2
[30]	FANALE M A,, HORWITZ S M,, FORERO-TORRES A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30⁺ peripheral T-cell lymphomas: results of a phase I study[J]. J Clin Oncol, 2014, 32(28): 3137-3143. doi: 10.1200/JCO.2013.54.2456
[31]	DUVIC M,, TETZLAFF M T,, GANGAR P, et al. Results of a phase Ⅱ trial of brentuximab vedotin for CD30⁺ cutaneous T-cell lymphoma and lymphomatoid papulosis[J]. J Clin Oncol, 2015, 33(32): 3759-3765. doi: 10.1200/JCO.2014.60.3787
[32]	PRINCE H M,, KIM Y H,, HORWITZ S M, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390(10094): 555-566. doi: 10.1016/S0140-6736(17)31266-7
[33]	HORWITZ S M,, ADVANI R H,, BARTLETT N L, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin[J]. Blood, 2014, 123(20): 3095-3100. doi: 10.1182/blood-2013-12-542142
[34]	ZINZANI P L,, SANTORO A,, GRITTI G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase Ⅱ CheckMate 436 study[J]. J Clin Oncol, 2019, 37(33): 3081-3089. doi: 10.1200/JCO.19.01492
[35]	KIM Y H,, TAVALLAEE M,, SUNDRAM U, et al. Phase Ⅱ investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project[J]. J Clin Oncol, 2015, 33(32): 3750-3758. doi: 10.1200/JCO.2014.60.3969
[36]	JACOBSEN E D,, SHARMAN J P,, OKI Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression[J]. Blood, 2015, 125(9): 1394-1402. doi: 10.1182/blood-2014-09-598763

Reference	Subtype	CD30 positive/%
Federico^[6]	Peripheral T-cell lymphoma-unspecified (PTCL-NOS)	59
	Angioimmunoblastic T-cell lymphoma (AITL)^*	76
Federico and Pongpruttipan^[6-7]	Extranodal NK/T cell lymphoma, nasal type (ENKTCL)	52-75
Ferreri and Delsol^[8-9]	ALCL, anaplastic lymphoma kinase (ALK)⁺/ALK^-	100
Sabattini^[10]	Enteropathy associated T-cell lymphoma (EATL)	54-100
Edinger^[11]	MF/Sézary syndrome	11-100
Cerroni^[12]	Transformative MF	100
El Shabrawi-Caelen^[13]	Lymphomatoid papulosis (LyP)	60-100
Slack, Campuzano-Zuluaga and Hu^[14⇓-16]	DLBCL	14-25
Slack^[14]	DLBCL, EB virus positive	90
Higgins^[17]	Primary mediastinal large B-cell lymphoma (PMBL)	69
Gardner^[18]	Follicular lymphoma (FL)	36-50

Reference	Study type	Pathological type	Case n	CD30 positive/%	ORR/PFS
Fanale^[30]	Ⅰ	PTCL	26	1	100.0%
Weisenburger^[22]		PTCL-NOS	340	20	Not reported
Duvic^[31]	Ⅱ	Cutaneous T-cell lymphoma	48	10	73.0%
Prince^[32]	Ⅲ	Cutaneous T-cell lymphoma	131	10	56.3%
Horwitz^[29]	Ⅲ	PTCL	452	10	PFS 48.2 month (vs 20.8 month)
Horwitz^[33]	Ⅱ	PTCL-NOS and PTCL-AITL	35	15%	41.0%
Zinzani^[34]	Ⅰ/Ⅱ	PMBL	30	1%	73.0%
Kim^[35]	Ⅱ	MF/Sézary syndrome	30	5%	70.0%
Campuzano-Zuluaga^[15]		DLBCL	167	20%	Not reported
Jacobsen^[36]	Ⅱ	Recurrent/refractory DLBCL	49	1%	44.0%

CD30在淋巴瘤中的表达及检测：现状与挑战

Detection of CD30 expression in lymphomas: status and challenges

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[2]	何丽媛, 王玉栋. ALK激酶域耐药突变的研究进展及未来应对策略[J]. 中国癌症杂志, 2022, 32(8): 736-746.
[3]	刘彦权, 胡晓梅, 殷悦, 林霖, 沈建箴, 陈玉婷, 唐焕文. 器官移植术后淋巴组织增生性疾病的临床回顾性研究[J]. 中国癌症杂志, 2022, 32(7): 650-656.
[4]	陈光亮, 吴方恬, 曹军宁. 非特指EBV阳性弥漫大B细胞淋巴瘤的研究进展[J]. 中国癌症杂志, 2022, 32(3): 258-267.
[5]	李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.
[6]	金正明. 淋巴瘤自体造血干细胞移植的临床实践优化探索与未来展望[J]. 中国癌症杂志, 2022, 32(2): 161-171.
[7]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[8]	谢梦青, 储香玲, 周　娟, 苏春霞. 小细胞肺癌免疫治疗相关生物标志物研究进展[J]. 中国癌症杂志, 2021, 31(7): 635-639.
[9]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[10]	何合胜, 杨玉琼, 刘银华, 靳小可, 徐又海, 姚军萍, 刘善浩, 严家炜, 黄东平 . 外周T细胞淋巴瘤合并自身免疫性溶血性贫血的临床特点分析[J]. 中国癌症杂志, 2021, 31(2): 121-125.
[11]	李　磊, 王　智, 由春媛 . 原发性心脏高级别B细胞淋巴瘤化疗缓解后复发1例报告[J]. 中国癌症杂志, 2021, 31(2): 156-160.
[12]	郭　晔, 张陈平 . 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识（2021年版）[J]. 中国癌症杂志, 2021, 31(12): 1220-1232.
[13]	李盼盼, 张　卓. 42例原发性中枢神经系统淋巴瘤患者预后影响因素分析[J]. 中国癌症杂志, 2021, 31(12): 1194-1201.
[14]	中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. 子宫内膜癌分子检测中国专家共识（2021年版）[J]. 中国癌症杂志, 2021, 31(11): 1126-1144.
[15]	张　欣, 周　成, 周恺乾, 柏乾明, 蒋冬先, 宿杰阿克苏, 侯英勇, 王　征, 纪　元 . 肉瘤样肝细胞癌中MET基因扩增与预后的相关性分析[J]. 中国癌症杂志, 2020, 30(9): 641-649.